Meeting
2020 Gastrointestinal Cancers Symposium
Phase I dose-escalation trial of trifluridine/tipiracil (TAS-102) and temozolomide in the treatment of advanced neuroendocrine tumors.
Authors
Nataliya Volodymyrivna Uboha
University of Wisconsin, Carbone Cancer Center, Madison, WI
Nataliya Volodymyrivna Uboha , Sam Joseph Lubner , Noelle K. LoConte , Daniel Mulkerin , Jens C. Eickhoff , Dustin A. Deming
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02943733
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 615)
Abstract #
615
Poster Bd #
F18
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Safety of trifluridine/tipiracil (TAS-102) in combination with temozolomide for metastatic neuroendocrine tumors.
First Author: Nataliya Volodymyrivna Uboha
Poster
2016 Gastrointestinal Cancers Symposium
A phase I study of veliparib (ABT-888) in combination with capecitabine (C) and temozolomide (T) in patients (pts) with advanced well-differentiated unresectable neuroendocrine tumors (wdNET).
First Author: Ramya Thota
Poster
2017 ASCO Annual Meeting
Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma multiforme.
First Author: Danielle A. Shafer
Poster
2015 ASCO Annual Meeting
Phase I clinical trial of temozolomide and methoxyamine (TRC-102) in patients with advanced solid tumors.
First Author: Jennifer Rachel Eads